Angiogenic biomarkers and healing of living cellular constructs

Journal of Dental Research

Volumn 90, Issue 4, 2011, Pages 456-462

  Morelli, T ^a,b   Neiva, R ^a,b   Nevins, M L ^c   McGuire, M K ^c   Scheyer, E T ^c   Oh, T J ^a,b   Braun, T M ^b   Nor J E ^b   Bates, D ^d   Giannobile, W V ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Organogenesis Inc ^*

^d ORGANOGENESIS INC   (United States)

Author keywords

angiogenesis; clinical trial; gingival recession; regeneration; regenerative medicine; tissue engineering; wound repair

Indexed keywords

EID: 79954586091     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034510389334     Document Type: Conference Paper

References (22)

1. Chirco R., Liu XW, Jung KK, Kim HR (2006). Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25: 99-113. (Pubitemid 43723986)
2. Cooke JW, Sarment DP, Whitesman LA, Miller SE, Jin Q., Lynch SE, et al. (2006). Effect of rhPDGF-BB delivery on mediators of periodontal wound repair. Tissue Eng 12: 1441-1450. (Pubitemid 44174780)
3. Falabella AF, Schachner LA, Valencia IC, Eaglstein WH (1999). The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch Dermatol 135: 1219-1222. (Pubitemid 29493282)
4. Falanga V., Margolis D., Alvarez O., Auletta M., Maggiacomo F., Altman M., et al. (1998). Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 134: 293-300. (Pubitemid 28141616)
5. Fivenson DP, Scherschun L., Choucair M., Kukuruga D., Young J., Shwayder T. (2003). Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol 48: 886-892. (Pubitemid 36706222)
6. Giannobile WV, Lynch SE, Denmark RG, Paquette DW, Fiorellini JP, Williams RC (1995). Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. J Clin Periodontol 22: 903-910.
7. Griffiths M., Ojeh N., Livingstone R., Price R., Navsaria H. (2004). Survival of Apligraf in acute human wounds. Tissue Eng 10: 1180-1195. (Pubitemid 39223796)
8. Izumi K., Feinberg SE, Iida A., Yoshizawa M. (2003). Intraoral grafting of an ex vivo produced oral mucosa equivalent: a preliminary report. Int J Oral Maxillofac Surg 32: 188-197. (Pubitemid 36592572)
9. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, et al. (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 (5089). 1798-1801. (Pubitemid 23087348)
10. Kumar I., Staton CA, Cross SS, Reed MW, Brown NJ (2009). Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds. Br J Surg 96: 1484-1491.
11. Li A., Dubey S., Varney ML, Dave BJ, Singh RK (2003). IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376. (Pubitemid 36302216)
12. McGuire MK, Nunn ME (2005). Evaluation of the safety and efficacy of periodontal applications of a living tissue-engineered human fibroblast-derived dermal substitute. I. Comparison to the gingival autograft: a randomized controlled pilot study. J Periodontol 76: 867-880.
13. McGuire MK, Scheyer ET, Nunn ME, Lavin PT (2008). A pilot study to evaluate a tissue-engineered bilayered cell therapy as an alternative to tissue from the palate. J Periodontol 79: 1847-1856.
14. McGuire MK, Scheyer ET, Nevins M., Neiva R., Cochran DL, Mellonig JT, et al. (2011). Living cellular construct for the treatment of mucogingival defects: results from a randomized, within-patient, controlled trial. J Periodontol (manuscript in review).
15. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA (1998). Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152: 1445-1452. (Pubitemid 28275003)
16. Osborne CS, Schmid P. (2002). Epidermal-dermal interactions regulate gelatinase activity in Apligraf, a tissue-engineered human skin equivalent. Br J Dermatol 146: 26-31. (Pubitemid 34158405)
17. Sabolinski ML, Alvarez O., Auletta M., Mulder G., Parenteau NL (1996). Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. Biomaterials 17: 311-320. (Pubitemid 26031385)
18. Sakai A., Ohshima M., Sugano N., Otsuka K., Ito K. (2006). Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. J Periodontol 77: 856-864. (Pubitemid 44740642)
19. Stetler-Stevenson WG (2008). Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1 (27). re6.
20. Stetler-Stevenson WG, Seo DW (2005). TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11: 97-103. (Pubitemid 40348986)
21. Szpaderska AM, Walsh CG, Steinberg MJ, DiPietro LA (2005). Distinct patterns of angiogenesis in oral and skin wounds. J Dent Res 84: 309-314. (Pubitemid 43822010)
22. Veves A., Falanga V., Armstrong DG, Sabolinski ML (2001). Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24: 290-295. (Pubitemid 32119127)